Mayo Clinic proceedings. Digital health

Body Weight and Blood Pressure Changes After Starting a Glucagon-Like Peptide 1 Drug: Analysis Using Data from Linked Devices

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated

Abstract

Real-world body composition and blood pressure changes were characterized following glucagon-like peptide (GLP)-1 receptor agonist initiation.

  • Body composition changes and blood pressure variations were observed after starting GLP-1 receptor agonists.
  • Connected device data may help identify predictors of quality weight loss.
  • The study characterizes patterns related to body composition and blood pressure in real-world settings.

Simplified

Full Text

We can’t show the full text here under this license.
View Full Text ↗

Related papers

Dec '20
Use of Glucagon-Like Peptide-1 Receptor Agonists in Japanese People with Type 2 Diabetes: A Retrospective Database Study
top 20% journal
cited by 17 papers
journal article
May '26
GLP-1 Agonist Use Is Not Linked to Better Paraspinal Muscle Quality in Diabetic Patients with Low Back Pain
top 30% journal
journal article
Oct '24
How a glucagon-like peptide 1 receptor drug may change body composition: A combined analysis
top 5% journal
cited by 35 papers
meta-analysis
May '26
Effects of GLP-1/GIP Treatment and Diet Advice on Body Fat and Muscle
journal article
Oct '25
Comparing lifestyle changes alone and with a diabetes drug on body composition in overweight adults
comparative study
Oct '25
Tirzepatide versus Semaglutide effects on blood sugar and weight in people with type 2 diabetes
top 20% journal
cited by 7 papers
journal article
May '26
Oral Nutritional Supplements and Body Weight and Muscle Changes in People Using GLP-1 Medicines: Real-World Data
top 30% journal
journal article
Apr '26
Changes in Body Fat and Metabolic Risk in Obese Teens Taking GLP-1 Medication
top 30% journal
journal article
Oct '25
Healthcare costs and treatment patterns linked to use of diabetes-related medication in patients with fatty liver disease and metabolism problems
top 30% journal
cited by 1 paper
journal article

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief